Loading…
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $109M | $17M | $5M | $19M | 4.0% | 18.8% | - |
| 2024 | $92M | $-9M | $-20M | $4M | -17.2% | 28.8% | - |
| 2023 | $72M | $-21M | $-18M | $-8M | -13.9% | 14.5% | - |
| 2022 | $62M | $-9M | $-11M | $10M | -9.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 62.45 | 71.52 | 92.13 | 109.43 |
| Cost Of Revenue | 23.48 | 28.62 | 32.75 | 35.83 |
| Gross Profit | 38.97 | 42.90 | 59.38 | 73.59 |
| Operating Expense | 51.26 | 60.42 | 65.59 | 61.53 |
| Operating Income | -12.29 | -17.52 | -6.22 | 12.06 |
| EBITDA | -9.42 | -21.31 | -8.90 | 16.57 |
| EBIT | -11.44 | -23.71 | -13.22 | 12.24 |
| Pretax Income | -11.44 | -25.16 | -19.39 | 6.95 |
| Tax Provision | 0 | -7.60 | 0.72 | 1.82 |
| Net Income | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income Common Stockholders | -11.44 | -17.57 | -20.11 | 5.13 |
| Total Expenses | 74.74 | 89.04 | 98.34 | 97.37 |
| Interest Expense | 0 | 1.45 | 6.16 | 5.29 |
| Interest Income | 0.85 | 2.19 | 0.33 | 0.35 |
| Selling General And Administration | 49.24 | 58.02 | 61.27 | 57.21 |
| Normalized EBITDA | -9.42 | -12.43 | -1.41 | 16.94 |
| Normalized Income | -11.44 | -11.37 | -14.19 | 5.40 |
| Basic EPS | -0.64 | -1.03 | -1.10 | 0.28 |
| Diluted EPS | -0.64 | -1.03 | -1.10 | 0.27 |
| Tax Effect Of Unusual Items | 0 | -2.68 | -1.57 | -0.10 |
| Tax Rate For Calcs | 0 | 0.30 | 0.21 | 0.26 |
| Total Unusual Items | 0 | -8.88 | -7.49 | -0.37 |
| Total Unusual Items Excluding Goodwill | 0 | -8.88 | -7.49 | -0.37 |
| Net Income From Continuing Operation Net Minority Interest | -11.44 | -17.57 | -20.11 | 5.13 |
| Reconciled Depreciation | 2.02 | 2.40 | 4.33 | 4.33 |
| Reconciled Cost Of Revenue | 23.48 | 28.62 | 32.75 | 35.83 |
| Net Interest Income | 0.85 | 0.74 | -5.83 | -4.94 |
| Net Income From Continuing And Discontinued Operation | -11.44 | -17.57 | -20.11 | 5.13 |
| Total Operating Income As Reported | -12.29 | -26.40 | -13.71 | 11.69 |
| Diluted Average Shares | 17.78 | 17.12 | 18.29 | 19 |
| Basic Average Shares | 17.78 | 17.12 | 18.29 | 18.56 |
| Diluted NI Availto Com Stockholders | -11.44 | -17.57 | -20.11 | 5.13 |
| Average Dilution Earnings | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income Continuous Operations | -11.44 | -17.57 | -20.11 | 5.13 |
| Other Income Expense | 0 | -8.38 | -7.34 | -0.17 |
| Other Non Operating Income Expenses | 0 | 0.50 | 0.15 | 0.20 |
| Special Income Charges | 0 | -8.88 | -7.49 | -0.37 |
| Gain On Sale Of Business | 0 | -2.14 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 6.74 | 7.49 | 0.37 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.85 | 0.74 | -5.83 | -4.94 |
| Interest Expense Non Operating | 0 | 1.45 | 6.16 | 5.29 |
| Interest Income Non Operating | 0.85 | 2.19 | 0.33 | 0.35 |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Depreciation Amortization Depletion Income Statement | 2.02 | 2.40 | 4.33 | 4.33 |
| Depreciation And Amortization In Income Statement | 2.02 | 2.40 | 4.33 | 4.33 |
| Selling And Marketing Expense | 0 | 0 | 0 | 0 |
| General And Administrative Expense | 49.24 | 58.02 | 61.27 | 57.21 |
| Other Gand A | 33.49 | 44.30 | 49.80 | 50.24 |
| Salaries And Wages | 15.75 | 13.72 | 11.47 | 6.96 |
| Operating Revenue | 62.45 | 71.52 | 92.13 | 109.43 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OptimizeRx Corporationthis co. | OPRX | $115M | 22.74 | 0.90 | 4.0% | 7.20 |
| TuHURA Biosciences, Inc. | HURA | $134M | - | 6.03 | -143.6% | -4.67 |
| AVITA Medical, Inc. | RCEL | $130M | - | -7.76 | 291.8% | -3.91 |
| The Joint Corp. | JYNT | $127M | - | 8.33 | 19.3% | 140.09 |
| Nano-X Imaging Ltd. | NNOX | $119M | - |
| 0.85 |
| -28.3% |
| -1.41 |
| Neuronetics, Inc. | STIM | $118M | - | 5.25 | -148.6% | -6.65 |
| Aardvark Therapeutics, Inc. | AARD | $114M | - | 1.07 | -54.0% | -0.07 |
| Cardiff Oncology, Inc. | CRDF | $111M | - | 2.44 | -101.0% | -1.10 |
| Definitive Healthcare Corp. | DH | $99M | - | 0.35 | -36.7% | 5.27 |
| Peer Median | - | - | 1.75 | -45.3% | -1.25 | |